These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2282 related items for PubMed ID: 20678680

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM, Boulet LP, Follows RM.
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.
    J Med Econ; 2011 Apr; 14(6):769-76. PubMed ID: 21942463
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K, Janson C, Lisspers K, Jørgensen L, Stratelis G, Telg G, Ställberg B, Johansson G.
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [Abstract] [Full Text] [Related]

  • 7. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 11. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ.
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [Abstract] [Full Text] [Related]

  • 12. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [Abstract] [Full Text] [Related]

  • 13. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
    Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, Sampalis JS.
    Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
    [Abstract] [Full Text] [Related]

  • 14. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V, Sangiorgi D, Buda S, Degli Esposti L.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul; 11():2749-2755. PubMed ID: 27853362
    [Abstract] [Full Text] [Related]

  • 15. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM.
    Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
    [Abstract] [Full Text] [Related]

  • 16. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE, Hagiwara M, Stanford RH, Stempel DA.
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [Abstract] [Full Text] [Related]

  • 17. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
    Hagiwara M, Delea TE, Stanford RH.
    J Asthma; 2013 Apr; 50(3):287-95. PubMed ID: 23305687
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
    Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, Strange C, Trudo F.
    Respir Res; 2015 Apr 23; 16(1):52. PubMed ID: 25899176
    [Abstract] [Full Text] [Related]

  • 19. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
    Nannini L, Lasserson TJ, Poole P.
    Cochrane Database Syst Rev; 2003 Apr 23; (4):CD003794. PubMed ID: 14583994
    [Abstract] [Full Text] [Related]

  • 20. Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.
    Simoni-Wastila L, Yang HW, Blanchette CM, Zhao L, Qian J, Dalal AA.
    Curr Med Res Opin; 2009 Nov 23; 25(11):2729-35. PubMed ID: 19778165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 115.